Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

XEOMIN should be discontinued and appropriate medical therapy immediately instituted.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [See Boxed Warning]. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. These reactions can occur within hours to weeks after injection with botulinum toxin.
  • Cervical Dystonia: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm:  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory comp
    '/>"/>

  • SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
    (Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
    (Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
    Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
    ... 13, 2011 BD (Becton, Dickinson and Company) (NYSE: ... a subsidiary of Waste Management, Inc. (NYSE: ... sharps waste from hospitals and other healthcare facilities.  The ... Solution, an innovative service that will recycle medical sharps ...
    ... Healthcare Financial Management Association (HFMA) has recognized the ... ("SIS") as once again consistently meeting the "Peer ... offerings as part of the annual evaluation process ... HFMA Peer Reviewed designation.  ...
    Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 2Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 3
    (Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
    (Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
    (Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
    (Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
    (Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
    Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
    ... Problems With Governor,s Mandatory Health Insurance Plan, ... today by the Schwarzenegger Administration fail to,protect patients ... decide which policies to cancel without prior review ... Consumer Rights (FTCR).,FTCR said that the weak cancellation ...
    ... Inc., an investment,company with a series of 20 ... by Standard & Poor,s, the calculating agent for ... trading on,Friday, October 26, 2007, Immunogen, Inc. (Nasdaq: ... BIVN ) in the HealthShares(TM) Emerging Cancer,Index. Bioenvision, ...
    ... Offers Tips for People with Diabetes Affected ... by California Wildfires, ... the following tips for people with diabetes who,are affected by the ... with diabetes,require additional supplies to manage their health. 1) Medication ...
    ... on November 13, 2007 at 8:00 am ... 9:00 pm (Beijing/Hong Kong), SHANGHAI, China, Oct. 23 ... ("WuXi PharmaTech" or "the Company"), the leading,China-based pharmaceutical and ... will release unaudited,financial results for the third quarter ended ...
    ... PDT (8:00 p.m. EDT), SUNNYVALE, Calif., Oct. 23 ... field of radiosurgery,announced today that it will host an investor ... the American Society of,Therapeutic Radiology and Oncology (ASTRO) in Los ... PDT. A live webcast of the presentation will begin ...
    ... -- Mayo Clinic today reported promising interim results from ... for patients with recurrent ovarian cancer that is resistant ... either complete or partial tumor regression from the therapy, ... this Phase 2 Consortium (P2C) clinical trial were presented ...
    Cached Medicine News:Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 2Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 3Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 3Health News:Emergency Preparedness for People With Diabetes 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 2Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 3Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2
    ... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
    ...
    ...
    ...
    Medicine Products: